The board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027.
Latest Zentalis Pharmaceuticals news
We have not published a story on Zentalis Pharmaceuticals yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.8 million, plus short-term investments of $149.8 million, $174.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Zentalis Pharmaceuticals
What is the ticker symbol of Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals, Inc. trades under the ticker ZNTL on NASDAQ.
Where is Zentalis Pharmaceuticals listed?
Zentalis Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Zentalis Pharmaceuticals?
The SEC Central Index Key (CIK) for Zentalis Pharmaceuticals, Inc. is 1725160. Its filings are on SEC EDGAR.
How many shares does Zentalis Pharmaceuticals have outstanding?
71,671,914 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Zentalis Pharmaceuticals listed under?
Our directory records Zentalis Pharmaceuticals, Inc. under United States.
What does Zentalis Pharmaceuticals do?
Our directory classifies Zentalis Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Zentalis Pharmaceuticals?
The ISIN recorded for Zentalis Pharmaceuticals, Inc. is US98943L1070.
Does aibio.space cover Zentalis Pharmaceuticals?
aibio.space lists Zentalis Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Zentalis Pharmaceuticals's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Zentalis Pharmaceuticals profitable?
Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for the fiscal year ended Dec 31, 2025, and used $125.2 million of cash in operations, per its annual report to the SEC.
How much does Zentalis Pharmaceuticals spend on research and development?
$107.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Zentalis Pharmaceuticals have?
$174.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Zentalis Pharmaceuticals (ZNTL) stock news?
Our latest story on Zentalis Pharmaceuticals, dated Jan 28, 2025: "Zentalis Pharmaceuticals announces restructuring with workforce reduction of approximately 40%". The board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027. Source.
How long will Zentalis Pharmaceuticals's cash last?
From our story of Jan 28, 2025: Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027. Source.
Is Zentalis Pharmaceuticals in financial distress?
Our latest distress story, dated Jan 28, 2025: "Zentalis Pharmaceuticals announces restructuring with workforce reduction of approximately 40%". The board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027. Source.
Investor discussion: Zentalis Pharmaceuticals
Members talk about Zentalis Pharmaceuticals (ZNTL). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Zentalis Pharmaceuticals, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Financings
Reported a financing. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ZNTL on TradingView.
SEC filings and registration
SEC name
Zentalis Pharmaceuticals, Inc.
CIK
1725160
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ZNTL (Nasdaq)
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121
Phone
(858) 263-4333
Shares outstanding
71,671,914 as of 2026-08-03 (10-Q filed 2026-08-06)
Former names
Zentalis Pharmaceuticals, LLC; Zeno Pharma, LLC
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Zentalis Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ZNTL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio